A behavioral economic analysis of the value-enhancing effects of nicotine and varenicline and the role of nicotinic acetylcholine receptors in male and female rats

Scott T. Barrett, Trevor N. Geary, Amy N. Steiner, Rick A. Bevins

Research output: Contribution to journalArticle

Abstract

Reinforcement value enhancement by nicotine of nonnicotine rewards is believed to partially motivate smoking behavior. Recently, we showed that the value-enhancing effects of nicotine are well characterized by reinforcer demand models and that the value-enhancing effects of the smoking-cessation aid bupropion (Zyban) are distinct from those of nicotine and differ between the sexes. The present study evaluated potential sex differences in the enhancement effects of nicotine and varenicline (Chantix) using a reinforcer demand methodology. The role of α4β2∗and α7 nicotinic acetylcholine receptors (nAChRs) in the enhancing effects of nicotine and varenicline is also evaluated. Male and female rats (n=12/sex) were trained to lever press maintained by sensory reinforcement by visual stimulus (VS) presentations. Changes in the VS value following nicotine and varenicline administration were assessed using an established reinforcer demand approach. Subsequently, the effects of antagonism of α4β2∗and α7 nAChRs on varenicline and nicotine-induced enhancement active lever-pressing were assessed using a progressive ratio schedule. Nicotine and varenicline enhanced VS demand equivalently between the sexes as evaluated by reinforcer demand. However, ∗receptor antagonism attenuated value enhancement by nicotine and varenicline in females, but only of nicotine in males.

LanguageEnglish (US)
Pages493-502
Number of pages10
JournalBehavioural Pharmacology
Volume29
Issue number6
DOIs
StatePublished - Sep 1 2018

Fingerprint

Behavioral Economics
Nicotinic Receptors
Nicotine
Varenicline
Bupropion
Smoking Cessation
Reward
Sex Characteristics
Appointments and Schedules

Keywords

  • behavioral economics
  • nicotine
  • nicotinic acetylcholine receptors
  • rat
  • reinforcer demand
  • reward enhancement
  • varenicline

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

A behavioral economic analysis of the value-enhancing effects of nicotine and varenicline and the role of nicotinic acetylcholine receptors in male and female rats. / Barrett, Scott T.; Geary, Trevor N.; Steiner, Amy N.; Bevins, Rick A.

In: Behavioural Pharmacology, Vol. 29, No. 6, 01.09.2018, p. 493-502.

Research output: Contribution to journalArticle

@article{4337c75318c8487a9b47c4246464be7d,
title = "A behavioral economic analysis of the value-enhancing effects of nicotine and varenicline and the role of nicotinic acetylcholine receptors in male and female rats",
abstract = "Reinforcement value enhancement by nicotine of nonnicotine rewards is believed to partially motivate smoking behavior. Recently, we showed that the value-enhancing effects of nicotine are well characterized by reinforcer demand models and that the value-enhancing effects of the smoking-cessation aid bupropion (Zyban) are distinct from those of nicotine and differ between the sexes. The present study evaluated potential sex differences in the enhancement effects of nicotine and varenicline (Chantix) using a reinforcer demand methodology. The role of α4β2∗and α7 nicotinic acetylcholine receptors (nAChRs) in the enhancing effects of nicotine and varenicline is also evaluated. Male and female rats (n=12/sex) were trained to lever press maintained by sensory reinforcement by visual stimulus (VS) presentations. Changes in the VS value following nicotine and varenicline administration were assessed using an established reinforcer demand approach. Subsequently, the effects of antagonism of α4β2∗and α7 nAChRs on varenicline and nicotine-induced enhancement active lever-pressing were assessed using a progressive ratio schedule. Nicotine and varenicline enhanced VS demand equivalently between the sexes as evaluated by reinforcer demand. However, ∗receptor antagonism attenuated value enhancement by nicotine and varenicline in females, but only of nicotine in males.",
keywords = "behavioral economics, nicotine, nicotinic acetylcholine receptors, rat, reinforcer demand, reward enhancement, varenicline",
author = "Barrett, {Scott T.} and Geary, {Trevor N.} and Steiner, {Amy N.} and Bevins, {Rick A.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1097/FBP.0000000000000404",
language = "English (US)",
volume = "29",
pages = "493--502",
journal = "Behavioural Pharmacology",
issn = "0955-8810",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - A behavioral economic analysis of the value-enhancing effects of nicotine and varenicline and the role of nicotinic acetylcholine receptors in male and female rats

AU - Barrett, Scott T.

AU - Geary, Trevor N.

AU - Steiner, Amy N.

AU - Bevins, Rick A.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Reinforcement value enhancement by nicotine of nonnicotine rewards is believed to partially motivate smoking behavior. Recently, we showed that the value-enhancing effects of nicotine are well characterized by reinforcer demand models and that the value-enhancing effects of the smoking-cessation aid bupropion (Zyban) are distinct from those of nicotine and differ between the sexes. The present study evaluated potential sex differences in the enhancement effects of nicotine and varenicline (Chantix) using a reinforcer demand methodology. The role of α4β2∗and α7 nicotinic acetylcholine receptors (nAChRs) in the enhancing effects of nicotine and varenicline is also evaluated. Male and female rats (n=12/sex) were trained to lever press maintained by sensory reinforcement by visual stimulus (VS) presentations. Changes in the VS value following nicotine and varenicline administration were assessed using an established reinforcer demand approach. Subsequently, the effects of antagonism of α4β2∗and α7 nAChRs on varenicline and nicotine-induced enhancement active lever-pressing were assessed using a progressive ratio schedule. Nicotine and varenicline enhanced VS demand equivalently between the sexes as evaluated by reinforcer demand. However, ∗receptor antagonism attenuated value enhancement by nicotine and varenicline in females, but only of nicotine in males.

AB - Reinforcement value enhancement by nicotine of nonnicotine rewards is believed to partially motivate smoking behavior. Recently, we showed that the value-enhancing effects of nicotine are well characterized by reinforcer demand models and that the value-enhancing effects of the smoking-cessation aid bupropion (Zyban) are distinct from those of nicotine and differ between the sexes. The present study evaluated potential sex differences in the enhancement effects of nicotine and varenicline (Chantix) using a reinforcer demand methodology. The role of α4β2∗and α7 nicotinic acetylcholine receptors (nAChRs) in the enhancing effects of nicotine and varenicline is also evaluated. Male and female rats (n=12/sex) were trained to lever press maintained by sensory reinforcement by visual stimulus (VS) presentations. Changes in the VS value following nicotine and varenicline administration were assessed using an established reinforcer demand approach. Subsequently, the effects of antagonism of α4β2∗and α7 nAChRs on varenicline and nicotine-induced enhancement active lever-pressing were assessed using a progressive ratio schedule. Nicotine and varenicline enhanced VS demand equivalently between the sexes as evaluated by reinforcer demand. However, ∗receptor antagonism attenuated value enhancement by nicotine and varenicline in females, but only of nicotine in males.

KW - behavioral economics

KW - nicotine

KW - nicotinic acetylcholine receptors

KW - rat

KW - reinforcer demand

KW - reward enhancement

KW - varenicline

UR - http://www.scopus.com/inward/record.url?scp=85051244766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051244766&partnerID=8YFLogxK

U2 - 10.1097/FBP.0000000000000404

DO - 10.1097/FBP.0000000000000404

M3 - Article

VL - 29

SP - 493

EP - 502

JO - Behavioural Pharmacology

T2 - Behavioural Pharmacology

JF - Behavioural Pharmacology

SN - 0955-8810

IS - 6

ER -